The Masonic Cancer Center (MCC) is an NCI-designated Comprehensive Cancer Center dedicated to cancer research, education, and patient care for the citizens of Minnesota and the surrounding region. Since the time of the first award in 1997, there has been growth of the membership and research base. In our original application, there were 89 members, this has increased to 229 members from 53 departments and 13 colleges and schools of the University of Minnesota. Since our last renewal, there has been growth in NCI-funded research from $35.5M to $41.1M, an increase of almost 16%. Total cancer related research funding has increased by 6% to $94.0 in 2017 from $88.7M in 2013. The MCC is organized into 6 Programs that focus on specific scientific themes: Screening, Prevention, Etiology and Cancer Survivorship; Carcinogenesis and Chemoprevention; Genetic Mechanisms; Cell Mechanisms: Immunology; and Transplant Biology and Therapy. These Programs are supported by 10 Shared Resources. The past funding period has seen increased emphasis on developing our translational pipeline. Several resources and organizational structures have been put into place to support this effort and to better connect the basic programmatic research with the clinic. These resources include a Cancer Research Translational Initiative to increase the number of investigator-initiated translational trials at MCC and the formation of Translational Working Groups that bring together researchers, clinicians, and others in the oncology community to solve problems in organ-site-specific cancers. We have also established several mechanisms to increase the involvement of the community, and particularly the underserved populations in our catchment area, in clinical research. The MCC is a successful matrix organization in a large public research university that engages its faculty to focus on the problem of cancer. Our last period of support has been characterized by growth, stability in our leadership, enhanced engagement of our community, and creation of several new cancer-focused initiatives.

Public Health Relevance

Overall Narrative The Masonic Cancer Center is an NCI-Designated Cancer Center that creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-22S3
Application #
10243556
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplant 53:1069-1071
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Springer, Simeon U; Chen, Chung-Hsin; Rodriguez Pena, Maria Del Carmen et al. (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7:
Widen, John C; Kempema, Aaron M; Baur, Jordan W et al. (2018) Helenalin Analogues Targeting NF-?B p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles. ChemMedChem 13:303-311
Nikodemova, Maria; Yee, Jeremiah; Carney, Patrick R et al. (2018) Transcriptional differences between smokers and non-smokers and variance by obesity as a risk factor for human sensitivity to environmental exposures. Environ Int 113:249-258
Xu, Bin; Magli, Alessandro; Anugrah, Yoska et al. (2018) Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy. Biomaterials 183:54-66
Lin, Lifeng; Chu, Haitao (2018) Bayesian multivariate meta-analysis of multiple factors. Res Synth Methods 9:261-272
Rashidi, Armin; Shanley, Ryan; Anasetti, Claudio et al. (2018) Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplant :
Kim, J-H; Frantz, A M; Sarver, A L et al. (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16:E176-E184
Mondragon-Gonzalez, Ricardo; Perlingeiro, Rita C R (2018) Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery. Dis Model Mech 11:

Showing the most recent 10 out of 1013 publications